Gossamer Bio GOSS 深 滬
已收盤 08-07 16:00:00 美东时间
0.178
0.000
-0.22%
華盛通- 最 高0.1816
- 今 開0.18
- 成交量 1093.95万股
- 最 低 0.1729
- 昨 收 0.1784
- 總市值 8701.47万
- 52周最高 3.87
- 市盈率 靜 --
- 換手率 2.24%
- 52周最低 0.1138
- 委 比 95.64%
- 總股本 4.89亿
- 歷史最高 27.15
- 量 比 0.74
- 振 幅 4.88%
- 歷史最低 0.1138
- 每 手 1
- 風險率 1.24%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅129.15%！HC Wainwright & Co.升Q32 Bio(QTTB)目标价至36美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Q32 Bio"买入"评级，目标价从13美元升至36美元；Chardan Capital：维持ProMIS Neurosciences"买入"评级，目标价从20美元升至33美元
07-29 11:37
美股大行评级 | ITG、Bending Spoons获多家大行首予买入评级；瑞银下调微软目标价从510美元降至480美元
今日重点评级关注：BTIG：上调Outlook Therapeutics"买入"评级，目标价4美元；TD Cowen：维持Nakamoto"买入"评级，目标价从1美元升至17美元
07-28 11:34
Gossamer Bio获FDA积极反馈，计划9月提交PAH新药上市申请
临床阶段生物制药公司Gossamer Bio今日宣布了一系列监管、战略及公司层面的重大更新。在与美国FDA进行卓有成效的Pre-NDA Type B会议并收...
07-27 21:56
Gossamer Bio Secures Stockholders Approval For Proposals Related To Convertible Note Exchange And Reverse Stock Split; Reports $57M Cash Position
Special Meeting: Approval of Proposals Related to Convertible Note Exchange and Reverse Stock Split At a special meeting held on July 14, 2026, Gossamer’s stockholders approved the proposals related to the previously completed exchange of its 5.00% Convertible Senior Notes due 2027 (the "2027 Notes"...
07-27 19:04
Gossamer Bio Advances Seralutinib Toward NDA In September 2026, Reacquires Global Rights To Seralutinib From Chiesi
– Pre-NDA Type B Meeting and FDA Minutes Provide Path to September 2026 NDA Submission for Seralutinib in PAH – – Gossamer Reacquires Worldwide Rights to Seralutinib, Aligning Global Commercial Control for a Potential First-in-Class Opportunity – – Stockholders Approved Proposals Related to Converti...
07-27 19:02
Gossamer Bio确定2030年可转换票据转换率及认股权证行权价
Gossamer Bio（纳斯达克代码：GOSS）宣布，已确定其2030年到期的7.50%优先担保可转换票据的初始转换率，以及相关认股权证的初始行权价格。...
07-01 21:47
美股大行评级 | 潜在涨幅135.66%！Ocular Therapeutix获Chardan Capital升目标价至23美元，维持"买入"评级
今日重点评级关注：Chardan Capital：维持Ocular Therapeutix"买入"评级，目标价从21美元升至23美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从30美元升至40美元
06-26 17:42
HC Wainwright & Co. Maintains Buy on Gossamer Bio, Lowers Price Target to $2
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Gossamer Bio (NASDAQ:GOSS) with a Buy and lowers the price target from $5 to $2.
06-26 00:32
Gossamer Bio Completes Debt Exchange, Converting $181M Of 2027 Notes Into New Secured Notes And Equity
Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today ...
06-17 20:15
